Equities research analysts expect Exelixis, Inc. (NASDAQ:EXEL) to report earnings per share (EPS) of $0.25 for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Exelixis’ earnings, with estimates ranging from $0.19 to $0.33. Exelixis reported earnings per share of $0.28 during the same quarter last year, which indicates a negative year over year growth rate of 10.7%. The company is expected to issue its next earnings report on Wednesday, August 7th.
On average, analysts expect that Exelixis will report full year earnings of $0.92 per share for the current fiscal year, with EPS estimates ranging from $0.77 to $1.05. For the next financial year, analysts forecast that the firm will report earnings of $1.02 per share, with EPS estimates ranging from $0.63 to $1.20. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Exelixis.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, May 1st. The biotechnology company reported $0.24 EPS for the quarter, meeting the consensus estimate of $0.24. The business had revenue of $215.49 million during the quarter, compared to analyst estimates of $206.06 million. Exelixis had a net margin of 75.97% and a return on equity of 37.21%. The business’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 earnings per share.
In other Exelixis news, insider Patrick J. Haley sold 2,000 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $25.00, for a total value of $50,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Alan M. Garber sold 30,000 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $23.99, for a total transaction of $719,700.00. Following the completion of the sale, the director now owns 76,329 shares of the company’s stock, valued at approximately $1,831,132.71. The disclosure for this sale can be found here. In the last 90 days, insiders sold 602,889 shares of company stock valued at $13,526,064. 4.50% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the business. Icon Wealth Partners LLC purchased a new stake in Exelixis in the 1st quarter worth approximately $27,000. FTB Advisors Inc. lifted its position in Exelixis by 312.0% in the 4th quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,170 shares in the last quarter. JOYN Advisors Inc. lifted its position in Exelixis by 334.2% in the 4th quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock worth $30,000 after buying an additional 1,173 shares in the last quarter. Kore Private Wealth LLC purchased a new stake in Exelixis in the 1st quarter worth approximately $36,000. Finally, Rockefeller Capital Management L.P. purchased a new stake in Exelixis in the 1st quarter worth approximately $40,000. Institutional investors own 78.27% of the company’s stock.
Shares of NASDAQ:EXEL traded down $0.02 during mid-day trading on Friday, hitting $19.79. The stock had a trading volume of 56,273 shares, compared to its average volume of 2,711,075. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.48 and a current ratio of 7.56. The company has a market cap of $6.19 billion, a PE ratio of 13.73, a price-to-earnings-growth ratio of 0.48 and a beta of 1.99. Exelixis has a 12-month low of $13.42 and a 12-month high of $25.31.
Exelixis Company Profile
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: Derivative
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.